T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G with the SEC on November 6, 2026, disclosing a 9.6% beneficial ownership position in Vaxcyte Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported 14,312,368 shares of Vaxcyte Inc. common stock beneficially owned.
  • Percent of class: The 14,312,368 shares represent 9.6% of the class, according to the filing.
  • Sole voting power: The filing reports sole voting power over 13,699,251 shares.
  • Sole dispositive power: Sole power to dispose or direct the disposition of 14,312,368 shares is reported.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type IA), incorporated in Maryland.

T. Rowe Price Investment Management Discloses Large Vaxcyte Holding in Amended 13G

According to the filing, T. Rowe Price Investment Management, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 2 to its Schedule 13G regarding its holdings in Vaxcyte Inc. (NASDAQ:PCVX), a company with principal executive offices at 825 Industrial Road, Suite 300, San Carlos, CA, 94070. The event triggering the filing occurred on September 30, 2026, and the statement was signed by Ellen York, Vice President, on November 6, 2026.

The filing reports that T. Rowe Price Investment Management, Inc. beneficially owns 14,312,368 shares of Vaxcyte Inc. common stock (CUSIP: 92243G108), equal to 9.6% of the class. Of those shares, the filer reports sole voting power over 13,699,251 shares, while sole dispositive power covers the full 14,312,368 shares. Shared voting power and shared dispositive power are each reported as 0.

The filing includes a certification stating that, "to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing further notes that T. Rowe Price Investment Management, Inc. "hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

What Was Disclosed

T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G disclosing beneficial ownership of 14,312,368 shares, or 9.6%, of Vaxcyte Inc. common stock, with the triggering event dated September 30, 2026.